OrganaBio has acquired Excellos for an undisclosed amount. This strategic move sees OrganaBio, a biotechnology company, integrate Excellos' specialized capabilities in human cell and tissue collection, manufacturing, and development services. Excellos, based in San Diego, is a unique full-service Contract Development and Manufacturing Organization (CDMO) dedicated to driving innovation in the cell and gene therapy industry.
Excellos' distinct offering is built upon the foundation of the San Diego Blood Bank, leveraging over 70 years of experience in blood and tissue handling. This provides exclusive access to one of the largest and most diverse donor pools available, alongside deep institutional expertise and connection to a public cord blood bank. The company focuses on supplying cGMP cellular products and services, coupled with process development and manufacturing expertise, to scientists and clinicians globally, supporting therapies from preclinical stages through phase II/III with clear scale-up pathways.
The acquisition is expected to create significant synergies, enhancing OrganaBio's comprehensive offerings in the life sciences sector. By integrating Excellos' critical human cell and tissue collection services with its manufacturing and development capabilities, OrganaBio gains a robust platform for sourcing high-quality, viable human cell and tissue samples. This integration is poised to streamline the supply chain for advanced cellular therapies and expand OrganaBio's capacity to support the development and commercialization of next-generation treatments.
This strategic purchase underscores OrganaBio's commitment to advancing cellular therapies. The combined entity is positioned to offer an unparalleled suite of services, from donor material acquisition and characterization to cGMP manufacturing, setting a new standard across the industry. The integration of Excellos' expertise and resources is anticipated to accelerate the realization of powerful therapeutic potentials, ultimately improving human life by facilitating the advancement of cellular and gene therapies.